Advertisement

The Use of Perinatal 6-Hydroxydopamine to Produce a Rodent Model of Lesch–Nyhan Disease

  • Darin J. KnappEmail author
  • George R. Breese
Part of the Current Topics in Behavioral Neurosciences book series (CTBN, volume 29)

Abstract

Lesch–Nyhan disease is a neurologically, metabolically, and behaviorally devastating condition that has eluded complete characterization and adequate treatment. While it is known that the disease is intimately associated with dysfunction of the hypoxanthine phosphoribosyltransferase 1 (HPRT1) gene that codes for an enzyme of purine metabolism (hypoxanthine-guanine phosphoribosyltransferase) and is associated with neurological, behavioral, as well as metabolic dysfunction, the mechanisms of the neurobehavioral manifestations are as yet unclear. However, discoveries over the past few decades not only have created useful novel animal models (e.g., the HPRT-deficient mouse and the serendipitously discovered perinatal 6-hydroxydopamine (6-OHDA lesion model), but also have expanded into epigenetic, genomic, and proteomic approaches to better understand the mechanisms underlying this disease. The perinatal 6-OHDA model, in addition to modeling self-injury and dopamine depletion in the clinical condition, also underscores the profound importance of development in the differential course of maladaptive progression in the face of a common/single neurotoxic insult at different ages. Recent developments from clinical and basic science efforts attest to the fact that while the disease would seem to have a simple single gene defect at its core, the manifestations of this defect are profound and unexpectedly diverse. Future efforts employing the 6-OHDA model and others in the context of the novel technologies of genome editing, chemo- and opto-genetics, epigenetics, and further studies on the mechanisms of stress-induced maladaptations in brain all hold promise in taking our understanding of this disease to the next level.

Keywords

Lesch–Nyhan disease Rats 6-hydroxydopamine 6-OHDA Perinatal Self-injurious behavior L-DOPA Animal models 

References

  1. Abel TJ, Dalm BD, Grossbach AJ, Jackson AE, Thomsen T, Greenlee JD (2014) Lateralized effect of pallidal stimulation on self-mutilation in Lesch-Nyhan disease. J Neurosurg Pediatr 14:594–597CrossRefGoogle Scholar
  2. Allen SM, Rice SN (1996) Risperidone antagonism of self-mutilation in a Lesch-Nyhan patient. Prog Neuropsychopharmacol Biol Psychiatry 20:793–800CrossRefGoogle Scholar
  3. Anderson LT, Ernst M (1994) Self-injury in Lesch-Nyhan disease. J Autism Dev Disord 24(1):67–81CrossRefGoogle Scholar
  4. Bitler CM, Howard BD (1986) Dopamine metabolism in hypoxanthine-guanine phosphoribosyltransferase-deficient variants of PC12 cells. J Neurochem 47:107–112CrossRefGoogle Scholar
  5. Breese GR, Baumeister AA, McCown TJ, Emerick SG, Frye GD, Mueller RA (1984) Neonatal-6-hydroxydopamine treatment: model of susceptibility for self-mutilation in the Lesch-Nyhan syndrome. Pharmacol Biochem Behav 21(3):459–461CrossRefGoogle Scholar
  6. Breese GR, Knapp DJ, Criswell HE, Moy SS, Papadeas ST, Blake BL (2005) The neonate-6-hydroxydopamine-lesioned rat: a model for clinical neuroscience and neurobiological principles. Brain Res Rev 48(1):57–73CrossRefGoogle Scholar
  7. Breese GR, Traylor TD (1970) Effect of 6-hydroxydopamine on brain norepinephrine and dopamine: evidence for selective degeneration of catecholamine neurons. J Pharmacol Exp Ther 174:413–420Google Scholar
  8. Breese GR, Traylor TD (1972) Developmental characteristics of brain catecholamines and tyrosine hydroxylase in the rat: effects of 6-hydroxydopamine. Br J Pharmcol 44:210–222CrossRefGoogle Scholar
  9. Ceballos-Picot I, Auge F, Fu R, Olivier-Bandini A, Cahu J, Chabrol B, Aral B, de Martinville B, Lecain JP, Jinnah HA (2013) Phenotypic variation among seven members of one family with deficiency of hypoxanthine-guanine phosphoribosyltransferase. Mol Genet Metab 110:268–274CrossRefGoogle Scholar
  10. Dammer EB, Göttle M, Duong DM, Hanfelt J, Seyfried NT, Jinnah HA (2015) Consequences of impaired purine recycling on the proteome in a cellular model of Lesch-Nyhan disease. Mol Genet Metab 114(4):570–579CrossRefGoogle Scholar
  11. Dauphinot L, Mockel L, Cahu J, Jinnah HA, Ledroit M, Potier MC, Ceballos-Picot I (2014) Transcriptomic approach to Lesch-Nyhan disease. Nucleosides, Nucleotides Nucleic Acids 33(4–6):208–217CrossRefGoogle Scholar
  12. Deisseroth K (2015) Optogenetics: 10 years of microbial opsins in neuroscience. Nat Neurosci 18(9):1213–1225CrossRefGoogle Scholar
  13. Devine DP (2012) Animal models of self-injurious behavior: an overview. Methods Mol Biol 829:65–84CrossRefGoogle Scholar
  14. Engle SJ, Womer DE, Davies PM, Boivin G, Sahota A, Simmonds HA, Stambrook PJ, Tischfield JA (1996) HPRT-APRT-deficient mice are not a model for Lesch-Nyhan syndrome. Hum Mol Genet 5:1607–1610CrossRefGoogle Scholar
  15. Ernst M, Zametkin AJ, Matochik JA, Pascualvaca D, Jons PH, Hardy K, Hankerson JG, Doudet DJ, Cohen RM (1996) Presynaptic dopaminergic deficits in Lesch-Nyhan disease. N Engl J Med 334(24):1568–1572CrossRefGoogle Scholar
  16. Fu R, Ceballos-Picot I, Torres RJ, Larovere LE, Yamada Y, Nguyen KV, Hegde M, Visser JE, Schretlen DJ, Nyhan WL, Puig JG, O’Neill PJ, Jinnah HA, Lesch-Nyhan Disease International Study Group (2014) Genotype-phenotype correlations in neurogenetics: Lesch-Nyhan disease as a model disorder. Brain 137:1282–1303Google Scholar
  17. Göttle M, Prudente CN, Fu R, Sutcliffe D, Pang H, Cooper D, Veledar E, Glass JD (2014) Loss of dopamine phenotype among midbrain neurons in Lesch-Nyhan disease. Ann Neurol 76(1):95–107CrossRefGoogle Scholar
  18. Guibinga GH (2015) MicroRNAs: tools of mechanistic insights and biological therapeutics discovery for the rare neurogenetic syndrome Lesch-Nyhan disease (LND). Adv Genet 90:103–131PubMedGoogle Scholar
  19. Hooper M, Hardy K, Handyside A, Hunter S, Monk M (1987) HPRT-deficient (Lesch-Nyhan) mouse embryos derived from germline colonization by cultured cells. Nature 326:292–295CrossRefGoogle Scholar
  20. Huang MM, Overstreet DH, Knapp DJ, Angel R, Wills TA, Navarro M, Rivier J, Vale W, Breese GR (2010) Corticotropin-releasing factor (CRF) sensitization of ethanol withdrawal-induced anxiety-like behavior is brain site specific and mediated by CRF-1 receptors: relation to stress-induced sensitization. J Pharmacol Exp Ther 332(1):298–307CrossRefGoogle Scholar
  21. Jinnah HA (2009) Lesch-Nyhan disease: from mechanism to model and back again. Dis Model Mech 2:116–121CrossRefGoogle Scholar
  22. Jinnah HA, Breese GR (1997) Anmal models for Lesch-Nyhan disease. In: Iannocconne PM, Scarpelli DG (eds) Biological aspects of disease: contributions from animcal models. Harwood Academic Publishers, Amersterdam, pp 94–143Google Scholar
  23. Jinnah HA, Friedmann T (2001) Lesch-Nyhan disease and its variants. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw Hill, New York, pp 2537–2570Google Scholar
  24. Jinnah HA, Hess EJ, Wilson MC, Gage FH, Friedmann T (1992) Localization of hypoxanthine-guanine phosphoribosyltransferase mRNA in the mouse brain by in situ hybridization. Mol Cell Neurosci 3:64–78CrossRefGoogle Scholar
  25. Jinnah HA, Page T, Friedmann T (1993) Brain purines in a genetic mouse model of Lesch-Nyhan disease. J Neurochem 60:2036–2045CrossRefGoogle Scholar
  26. Jinnah HA, Yitta S, Drew T, Kim BS, Visser JE, Rothstein JD (1999a) Calcium channel activation and self-biting in mice. Proc Nat Acad Sci USA 96:15228–15232CrossRefGoogle Scholar
  27. Jinnah HA, Jones MD, Wojcik BE, Rothstein JD, Hess EJ, Friedmann T, Breese GR (1999b) Influence of age and strain on striatal dopamine loss in a genetic mouse model of Lesch-Nyhan disease. J Neurochem 72:225–229CrossRefGoogle Scholar
  28. Kang TH, Friedmann T (2015) Alzheimer’s disease shares gene expression aberrations with purinergic dysregulation of HPRT deficiency (Lesch-Nyhan disease). Neurosci Lett 590:35–39CrossRefGoogle Scholar
  29. Kang TH, Park Y, Bader JS, Friedmann T (2013) The housekeeping gene hypoxanthine guanine phosphoribosyltransferase (HPRT) regulates multiple developmental and metabolic pathways of murine embryonic stem cell neuronal differentiation. PLoS ONE 8(10):e74967CrossRefGoogle Scholar
  30. Knapp DJ, Overstreet DH, Angel RA, Navarro M, Breese GR (2007) The amygdala regulates the antianxiety sensitization effect of flumazenil during repeated chronic ethanol or repeated stress. Alcohol Clin Exp Res 31(11):1872–1882CrossRefGoogle Scholar
  31. Knapp DJ, Whitman BA, Wills TA, Angel RA, Overstreet DH, Criswell HE, Ming Z, Breese GR (2011a) Cytokine involvement in stress may depend on corticotrophin releasing factor to sensitize ethanol withdrawal anxiety. Brain Behav Immun 25(Suppl 1):S146–S154CrossRefGoogle Scholar
  32. Knapp DJ, Overstreet DH, Huang M, Wills TA, Whitman BA, Angel RA, Sinnett SE, Breese GR (2011b) Effects of a stressor and corticotrophin releasing factor on ethanol deprivation-induced ethanol intake and anxiety-like behavior in alcohol-preferring P rats. Psychopharmacology 218(1):179–189CrossRefGoogle Scholar
  33. Kuehn MR, Bradley A, Robertson EJ, Evans MJ (1987) A potential animal model for Lesch-Nyhan syndrome through introduction of HPRT mutations into mice. Nature 326:295–298CrossRefGoogle Scholar
  34. Lee HM, Giguere PM, Roth BL (2014) DREADDs: novel tools for drug discovery and development. Drug Discov Today 19(4):469–473CrossRefGoogle Scholar
  35. Lewers JC, Ceballos-Picot I, Shirley TL, Mockel L, Egami K, Jinnah HA (2008) Consequences of impaired purine recycling in dopaminergic neurons. Neuroscience 152:761–772CrossRefGoogle Scholar
  36. Lloyd KG, Hornykiewicz O, Davidson L, Shannak K, Farley I, Goldstein M, Shibuya M, Kelley WN, Fox IH (1981) Biochemical evidence of dysfunction of brain neurotransmitters in the Lesch-Nyhan syndrome. N Engl J Med 305(19):1106–1111CrossRefGoogle Scholar
  37. Muehlmann AM, Kies SD, Turner CA, Wolfman S, Lewis MH, Devine DPM (2012) Self-injurious behaviour: limbic dysregulation and stress effects in an animal model. J Intellect Disabil Res 56(5):490–500CrossRefGoogle Scholar
  38. Murlidharan G, Samulski RJ, Asokan A (2014) Biology of adeno-associated viral vectors in the central nervous system. Front Mol Neurosci 7:76CrossRefGoogle Scholar
  39. Nguyen KV (2015) Epigenetic regulation in amyloid precursor protein with genomic rearrangements and the Lesch-Nyhan syndrome. Nucleosides, Nucleotides Nucleic Acids 34(10):674–690CrossRefGoogle Scholar
  40. Papadeas ST, Breese GR (2014) 6-Hydroxydopamine lesioning of dopamine neurons in neonatal and adult rats induces age-dependent consequences. In: Kostrzewa RM (ed) Handbook of neurotoxicity. Springer, New York, pp 133–198Google Scholar
  41. Piedimonte F, Andreani JC, Piedimonte L, Micheli F, Graff P, Bacaro V (2015) Remarkable clinical improvement with bilateral globus pallidus internus deep brain stimulation in a case of Lesch-Nyhan disease: five-year follow-up. Neuromodulation 18:118–122CrossRefGoogle Scholar
  42. Pozzi M, Piccinini L, Gallo M, Motta F, Radice S, Clementi E (2014) Treatment of motor and behavioural symptoms in three Lesch-Nyhan patients with intrathecal baclofen. Orphanet J Rare Dis 9:208CrossRefGoogle Scholar
  43. Saito Y, Ito M, Hanaoka S, Ohama E, Akaboshi S, Takashima S (1999) Dopamine receptor upregulation in Lesch-Nyhan syndrome: a postmortem study. Neuropediatrics 30:66–71CrossRefGoogle Scholar
  44. Schretlen FJ, Varvaria M, Te Ho, Vannorsdall TD, Gordon B, Harris JC, Jinnah HA (2013) Regional brain volume abnormalities in Lesch-Nyhan disease and its variants: a cross-sectional study. Lancet Neurol 12:1151–1158CrossRefGoogle Scholar
  45. Schretlen DJ, Varvaris M, Vannorsdall TD, Gordon B, Harris JC, Jinnah HA (2015) Brain white matter volume abnormalities in Lesch-Nyhan disease and its variants. Neurology 84:190–196CrossRefGoogle Scholar
  46. Shirley TL, Lewers JC, Egami K, Majumdar A, Kelly M, Ceballos-Picot I, Seidman MM, Jinnah HA (2007) A human neuronal tissue culture model for Lesch-Nyhan disease. J Neurochem 101:841–853CrossRefGoogle Scholar
  47. Stodgell CJ, Loupe PS, Schroeder SR, Tessel RE (1998) Cross-sensitization between footshock stress and apomorphine on self-injurious behavior and neostriatal catecholamines in a rat model of Lesch-Nyhan syndrome. Brain Res 783(1):10–18CrossRefGoogle Scholar
  48. Surmeier DJ, Ding J, Day M, Wang Z, Shen W (2007) D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci 30(5):228–235CrossRefGoogle Scholar
  49. Torres RJ, Puig JG (2015) Hypoxanthine deregulates genes involved in early neuronal development: implications in Lesch-Nyhan disease pathogenesis. J Inherit Metab Dis 38:1109–1118CrossRefGoogle Scholar
  50. Trigueros Genao M, Torres RJ (2014) From genotype to phenotype; clinical variability in Lesch-Nyhan disease. The role of epigenetics. Rev Clin Esp 214:461–465CrossRefGoogle Scholar
  51. Tschirner SK, Gutzki F, Kaever V, Seifert R, Schneider EH (2015) Altered histamine neurotransmission in HPRT-deficient mice. Neurosci Lett 609:74–80CrossRefGoogle Scholar
  52. Urban DJ, Roth B (2015) DREADDs (designer receptors exclusively activated by designer drugs): chemogenetic tools with therapeutic utility. Annu Rev Pharmacol Toxicol 55:399–417CrossRefGoogle Scholar
  53. Weinberg MS, Samulski RJ, McCown TJ (2013) Adeno-associated virus (AAV) gene therapy for neurological disease. Neuropharmacology 69:82–88CrossRefGoogle Scholar
  54. Wong DF, Harris JC, Naidu S, Yokoi F, Marenco S, Dannals RF, Ravert HT, Yaster M, Evans A, Rousset O et al (1996) Dopamine transporters are markedly reduced in Lesch-Nyhan disease in vivo. Proc Nat Acad Sci USA 93:5539–5543CrossRefGoogle Scholar
  55. Yeh J, Zheng S, Howard BD (1998) Impaired differentiation of HPRT-deficient dopaminergic neurons: a possible mechanism underlying neuronal dysfunction in Lesch-Nyhan syndrome. J Neurosci Res 53:78–85CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.School of Medicine, Department of Psychiatry and Bowles Center for Alcohol StudiesUniversity of North CarolinaChapel HillUSA

Personalised recommendations